Recurrent respiratory papillomatosis. Benign neoplasm of middle ear and respiratory system (adenomatose polyps)
Conditions
Interventions
One group included.
Contovir group:
Contovir: combination of ethanol extract of Rosa sp., urtica dioica and tanacetum vulgare.
The initial dose of CONTOVIR was 1.5 IV. Since it causes phlebitis in chi
Treatment - Drugs
One group included.
Contovir group:
Contovir: combination of ethanol extract of Rosa sp., urtica dioica and tanacetum vulgare.
The initial dose of CONTOVIR was 1.5 IV. Since it causes phlebitis in
Sponsors
Ear, nose, throat, head and neck department and research center of Iran University of Medical Scienc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- all patients with Recurrent Respiratory Papillomatosis diagnosed by 2 ENT specialist. Exclusion Criteria: 1- No other severe respiratory disease (TB, ...). 2- No other severe inflammatory disease (RA, SLE, ...). 3- No history of surgery during the treatment time of treatment and one year before the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of RRP recurrence. Timepoint: Surgeries during one year after adjuvant therapy. Method of measurement: Calender. | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease severity. Timepoint: Clinical (voice and auscultation) Anatomical (number and type of polyps). Method of measurement: staging system described by Derkay et al (Derkay, D.A.L.a.C.S., Epidemiology of recurrent respiratory papillomatosis. APMIS, 2010. 118: p. 450-454.). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Aslan Ahmadi
ENT-Head and Neck Surgery Research Center, Iran University of Medical Sciences
Outcome results
None listed